Media & Press relations

Swipe for more

• August 18, 2025

  bioMérieux receives U.S. 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

  bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for the addition of Anterior Nasal Swab (ANS) as a validated specimen type for this panel, specifically for use with the respiratory test menu.

  Read more
  

• August 06, 2025

  bioMérieux Develops Game Changing Quality Control Solution GENE-UP^® PRO HRM

  bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce the launch of GENE-UP^® PRO HRM—the first DNA-based test commercially developed to detect heat-resistant molds at the molecular level.

  Read more
  

• August 06, 2025

  bioMérieux Recognized for Best System Performance and Best Service with 2025 IMV ServiceTrak™ Clinical Laboratory Awards

  bioMérieux received two 2025 IMV ServiceTrak™ Clinical Laboratory Awards for excellence in Immunoassay, highlighting bioMérieux’s continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.

  Read more